BEIJING, June 23 (Reuters) - China's National Medical
Products Administration (NMPA) said on Wednesday it has approved
the first CAR-T cell therapy in the country.
The drug Yescarta is approved to treat adult patients with
relapsed or refractory large B-cell lymphoma after two or more
lines of systemic therapy, NMPA said in a statement on its
A joint venture of Shanghai Fosun Pharmaceutical Group
has obtained the rights from Kite Pharma, a
subsidiary of U.S. drugmaker Gilead, to sell the therapy in
China, Hong Kong and Macau, and plans production in mainland
China, Fosun Pharma filings showed.
(Reporting by Roxanne Liu and Ryan Woo; Editing by Jacqueline